Table 3.
Association of anti-spike antibody levels with baseline characteristics and comorbidities in post-COVID-19 non-vaccinated, vaccinated (both single and two-dose vaccinated) and COVID-19-naïve two-dose vaccinated KTRs. The data shown corresponds to anti-spike antibody titres (AU/mL)
| Post-COVID-19 KTRs | ||||||
|---|---|---|---|---|---|---|
| Characteristics | Non-vaccinated n = 57 | P-value | Vaccinated (single-dose and two-dose vaccinated) n = 48 | P-value | COVID-19-naïve two-dose vaccinated n = 103 | P-value |
| Demographics | ||||||
| Age | ||||||
| <60 years | 768 (250–2228) n = 47 | 0.973 | 3697 (716–10 450) n = 37 | 0.873 | 57.90 (2.23–2551) n = 92 | 0.184 |
| >60 years | 499 (153–6348) n = 10 | 3540 (371–10 626) n = 11 | 3.90 (0.80–220.0) n = 11 | |||
| Gender | ||||||
| Male | 768 (250–1941) n = 39 | 0.993 | 3697 (974–10 360) n = 35 | 0.719 | 87.2 (1.35–2756) n = 70 | 0.522 |
| Female | 694 (184.8–4294) n = 17 | 2298 (426–12 220) n = 13 | 6.80 (2.0–1339) n = 33 | |||
| Transplant duration | ||||||
| ≤1 year | 1710 (523–10 760) n = 5 | 0.284 | Three cases | 0.841 | NA | NA |
| >1 year | 745 (249–2228) n = 51 | 3540 (716–10 450) n = 45 | NA | |||
| Vaccination detailsAnti-spike antibody levels (AU/mL) from onset of COVID (weeks) | ||||||
| <12 weeks | 768 (205–3168) n = 31 | 0.921 | 3114 (633–6188) n = 10 | 0.339 | NA | NA |
| >12–24 weeks | 1132 (249–1941) n = 11 | 750 (519–4835) n = 7 | NA | |||
| >24 weeks | 750 (382–9774) n = 15 | 5883 (1233–10 780) n = 31 | NA | |||
| Anti-spike antibody levels from last vaccine dose (days) | ||||||
| <21 days | NA | NA | 3619 (510–7960) n = 10 | 0.910 | 31.1 (0.08–1191) n = 10 | 0.280 |
| >21 days | NA | 3741 (733–10 560) n = 38 | 17.1 (1.9–2534) n = 93 | |||
| Comorbidities | ||||||
| Any | ||||||
| Present | 76 (250–2390) n = 50 | 0.969 | 3697 (682–10 550) n = 47 | NA | 17.10 (1.90–1801) N = 91 | 0.930 |
| Absent | 1228 (66.8–4508) n = 6 | One-case only | 390.9 (0.70–3416) n = 12 | |||
| DM | ||||||
| Present | 7680 (238–1772) n = 29 | 0.825 | 3481 (532–5403) n = 25 | 0.197 | 119 (4.0–4710) n = 45 | 0.022 |
| Absent | 745 (250–4150) n = 29 | 7022 (1233–12 120) n = 23 | 8.0 (0.40–839.5) n = 58 | |||
| HTN | ||||||
| Present | 754 (249–2228) n = 47 | 0.713 | 3697 (614–10 580) n = 45 | 0.873 | 23.5 (1.80–2219) n = 86 | 0.657 |
| Absent | 1710 (181–4294) n = 9 | 3436 n = 3a | 4.40 (1.0–2214) n = 17 | |||
| CLD | ||||||
| Present | 1196 (645–4680) n = 5 | 0.339 | Only two cases | 0.255 | 5.0 (0.8–52.10) n = 6 | 0.084 |
| Absent | 745 (228–2228) n = 51 | 3706 (733–10 560) n = 46 | 56.10 (2.05–2534) n = 97 | |||
| COAD | ||||||
| Present | Two cases | 0.026 | 4234 (371–10 620) n = 7 | 0909 | One case | 0.719 |
| Absent | 877 (273–2950) n = 54 | 3540 (862–10 450) n = 41 | 17.0 (1.6–2219) n = 102 | |||
| Vascular disease (CAD/PVD) | ||||||
| Present | 164 (128– 5321) n = 5 | 0.449 | 2997 (480–6472) n = 14 | 0.297 | Two cases | 0.038 |
| Absent | 768 [280–2877] n = 51 | 3628 (918–11 110) n = 34 | 16.90 (1.6–1759) n = 101 | |||
| Chronic allograft dysfunction | ||||||
| Present | 1196 (515–6791) n = 11 | 0.348 | 4000 (2700–10 780) n = 11 | 0.244 | 100.5 (0.40–978.9) n = 35 | 0.473 |
| Absent | 754 (216–2552) n = 45 | 3481 (583–9172) n = 37 | 16.45 (2.0–2595) n = 68 | |||
aIQR could not be calculated due to insufficient n values.